Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non Operating Income (2018 - 2025)

Arcturus Therapeutics Holdings' Non Operating Income history spans 8 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 52.61% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $10.1 million, down 33.57%, while the annual FY2025 figure was $10.1 million, 33.56% down from the prior year.
  • Non Operating Income reached $1.5 million in Q4 2025 per ARCT's latest filing, down from $3.2 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $6.9 million in Q4 2023 to a low of -$564000.0 in Q1 2022.
  • Average Non Operating Income over 5 years is $2.0 million, with a median of $2.5 million recorded in 2023.
  • Peak YoY movement for Non Operating Income: crashed 2281.82% in 2021, then soared 1340.19% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$524000.0 in 2021, then skyrocketed by 295.61% to $1.0 million in 2022, then skyrocketed by 571.32% to $6.9 million in 2023, then crashed by 53.29% to $3.2 million in 2024, then crashed by 52.61% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Non Operating Income are $1.5 million (Q4 2025), $3.2 million (Q3 2025), and $2.6 million (Q2 2025).